BioCentury
ARTICLE | Clinical News

Roche drops aleglitazar

July 11, 2013 12:02 AM UTC

Roche (SIX:ROG; OCTQX:RHHBY) discontinued development of aleglitazar after an independent DSMB recommended stopping early the Phase III AleCardio trial evaluating the diabetes compound due to "safety ...